Ebba Biotech welcomes you to tune in to our webinar featuring Assistant Professor Oxana Klementieva from Lund's University.

During her talk titled "Amytracker - A New Frontier in Imaging of Amyloid Structures in Tissues", Oxana Klementieva will detail her cutting-edge research into mechanisms of amyloid aggregation using novel imaging techniques.

Read more about her work here:

• MMS Lab: https://mmslab.net/
• Medical Microspectroscopy: https://www.lunduniversity.lu.se/luca...
• NanoLund: https://www.nano.lu.se/start

About Oxana Klementieva I am an Associate Professor in the Department of Experimental Medicine at Lund University. I did my Ph.D. in 2012 in Barcelona and moved to Lund as a postdoc. In 2018, I established a successful research group, the Medical Micro-spectroscopy Lab (MMS Lab) at Lund University’s Medical Faculty. Our research goal is the methodological development of novel approaches that allow the study of amyloid aggregation at the nanoscale in neurons and tissues; more about the project on our website is mmslab.net. The lab currently comprises a team of researchers including BSc, MSc, PhD, and postdoctoral researchers.We utilize cutting-edge technologies available at synchrotron facilities MAX IV in Lund and SOLEIL in France. Our efforts have resulted in the development of a label-free super-resolution amyloid structure imaging approach, enabling direct imaging within neurons and tissues. Our work has been published in prestigious journals, including Nature Communications, Advanced Science, Acta Neuropathologica, Nature: Light, Science & Applications, and we also have a submission under review at JACS.

Ebba Biotech's first webinar in 2023 is dedicated to "Amyloid Fibril Polymorphism" which has recently been shown to be a hallmark of many proteinopathies. One of the leading authorities in this field is Professor Per Hammarström from Linköping University. During this talk titled "Amyloid fibril polymorphism in proteinopathies", Prof. Hammarström discusses his work with protein misfolding in different amyloid diseases and various enhanced analytical methods pushing the boundaries within the amyloid field. Read more about his work using an Amytracker-like molecule for Advanced Imaging of amyloid aggregates here.

Ebba Biotech welcomes you to listen to Prof. Resia Pretorius present her research findings using the Amytracker molecules. Her presentation titled “Consequences of coagulation in health and disease: The use of fluorescent markers” will detail past work with the Amytracker molecules within her group and her new exciting work with Long Covid patients.

DISCLAIMER: Prof. Pretorius presentation is purely research based and for informational purposes only. This presentation contains no clinical advice for patients. If you have any health issues please contact your healthcare providers.

On the first of June 2021, Ferdinand Choong, Ebba Biotech's co-founder, and Assistant Professor at Karolinska Institutet and AIMES (Center for the Advancement of Integrated Medical and Engineering), presented his research using Ebba Biotech's optotracers at the digital event Lab & Diagnostics of the Future 2021, held by Life Science Sweden.

At this event, Ferdinand spoke about Ebba Biotech's optotracers multifunctional tracer for disease research and diagnostics. He explains the technical concept in large and Ebba Biotech's three product series,

Amytracker - used to detect amyloids and other protein aggregates,
Ebba Biolight - used to detect bacteria and biofilm,
Carbotrace - used for mapping composition of biobased material.

At AIMES, Ferdinand is applying optotracing to improve research and diagnostics of infection, where bacterial infection has a significant role, and biofilm might be the key reason why bacterial infection exists, which he describes in more detail.

A paper in the scientific video journal Jove (Nyström et al. (2017) Jove 128, 1–7) describes the application of Amytracker-like Molecules in combination with fluorescence microscopy techniques for detection and exploration of protein aggregates.

Peter Nilson has been elected as future research leader from the Swedish Foundation for Strategic Research (SSF). His work about the development of multifunctional tools for diagnosis and therapy has led to the development of our Amytracker molecules.